Synthesis and structure-activity relationships of pyrazine-pyridine biheteroaryls as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors

Journal of Medicinal Chemistry

Volumn 48, Issue 15, 2005, Pages 4892-4909

  Kuo, Gee Hong ^a   Prouty, Catherine ^a   Wang, Aihua ^a   Emanuel, Stuart ^a   DeAngelis, Alan ^a   Zhang, Yan ^a   Song, Fengbin ^a   Beall, Lawrence ^a   Connolly, Peter J ^a   Karnachi, Prahba ^a   Chen, Xin ^a   Gruninger, Robert H ^a   Sechler, Jan ^a   Fuentes Pesquera, Angel ^a   Middleton, Steven A ^a   Jolliffe, Linda ^a   Murray, William V ^a  

^a Drug Discovery Raritan   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [5 [6 (CHLOROPHENYLAMINO)PYRAZIN 2 YL]PYRIDIN 3 YLAMINO]BUTAN 1 OL; CYTOTOXIC AGENT; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR KINASE; GLYCOGEN SYNTHASE KINASE 3; N [5 [6 (3 CHLOROPHENYLAMINO)PYRAZIN 2 YL]PYRIDIN 3 YL] N',N' DIMETHYLETHANE 1,2 DIAMINE; PALLADIUM; PHOSPHOTRANSFERASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR KINASE; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; PYRAZINE DERIVATIVE; PYRIDINE DERIVATIVE; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 2 BLOCKING AGENT;

ADOLESCENT; ANGIOGENESIS; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CATALYSIS; CELL GROWTH; CELL STRAIN A375; CELL STRAIN HCT116; CHEMICAL BOND; DRUG SELECTIVITY; DRUG SYNTHESIS; ENDOTHELIUM CELL; ENZYME INHIBITION; EXPERIMENTAL MELANOMA; FEMALE; HELA CELL; HUMAN; HUMAN CELL; HUMAN UMBILICAL VEIN ENDOTHELIUM CELL; MOLECULAR MODEL; MOUSE; NONHUMAN; NUDE MOUSE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT;

AMINOPYRIDINES; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MICE; MICE, NUDE; MODELS, MOLECULAR; PYRAZINES; PYRIDINES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 22744457026     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm058205b     Document Type: Article

References (59)

1. Risau, W. Mechanism of angiogenesis. Nature 1997, 386, 671-674.
2. Ribatti, D.; Vacca, A.; Nico, B.; Roncali, L.; Dammacco, F. Postnatal angiogenesis. Mech. Dev. 2001, 100, 157-163.
3. (a) Folkman, J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann. Surg. 1972, 175, 409-416.
4. (b) Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971, 285, 1182-1186.
5. Spranger, J.; Pfeiffer, A. F. New concepts in pathogenesis and treatment of diabetic retinopathy. Exp. Clin. Endocrinol. Diabetes 2001, 109 (Suppl. 2) S438-S450.
6. Walsh, D. A.; Haywood, L. Angiogenesis: a therapeutic target in arthritis. Curr. Opin. Invest. Drugs 2001, 2, 1054-1063.
7. McLaren, J.; Prentice, A.; Charnock-Jones, D. S.; Millican, S. A.; Muller, K. H.; Sharkey, A. M.; Smith, S. K. Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids. J. Clin. Invest. 1996, 98, 482-489.
8. Detmar, M. The role of VEGF and thrombospondin in skin angiogenesis. Dermatol. Sci. 2000, 24, S78-S84.
9. Folkman, J. What is the evidence that tumors are angiogenesis dependment? J. Natl. Cancer Inst. 1990, 82, 4-6.
10. Liotta, L. A.; Steeg, P. S.; Stetler-Stevenson, W. G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991, 64, 327-336.
11. (a) Nugent, M. A.; Iozzo, R. V. Fibroblast growth factor-2. Int. J. Biochem. Cell. Biol. 2000, 32, 115-120.
12. (b) Carmeliet, P. Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 2000, 6, 389-395.
13. (c) Davis, S.; Yancopoulos, G. D. The angiopoietins: yin and yang in angiogenesis. Curr. Top. Microbiol. Immunol. 1999,237, 173-185.
14. (d) Lindahl, P.; Bostrom, H.; Karlsson, L.; Hellstrom, M.; Kalen, M.; Betsholtz, C. Role of platelet-derived growth factors in angiogenesis and alveogenesis. Curr. Top. Pathol. 1999, 93, 27-33.
15. (a) Cross, M. J.; Claesson-Welsh, L. FGF and VEGF function in angiogenesis: signaling pathways, biological responses, and therapeutic inhibition. Trends Pharm. Sci. 2001, 22, 201-207.
16. (b) McMahon, G. VEGF receptor signaling in tumor angiogenesis. Oncologist 2000, 5 (Suppl. 1), 3-10.
17. Ferrara, N.; Davis-Smyth, T. The biology of vascular endothelial growth factor. Endocrinol. Rev. 1997, 18, 4-25.
18. De Vries, C.; Escobedo, J. A.; Ueno, H.; Houck, K.; Ferrara, N.; Williams, L. T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992, 255, 989-991.
19. Shalaby, F.; Rossant, J.; Yamaguchl, T. P.; Gertsenstein, M.; Wu, X.-F.; Breltman, M. L.; Schuh, A. C. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995, 376, 62-66.
20. Ferrara, N.; Gerber, H.-P.; LeCouter, J. The biology of VEGF and its receptors. Nat. Med. 2003, 9, 669-676.
21. Kerbel, R. S. A cancer therapy resistant to resistance. Nature 1997, 390, 335-336.
22. Yang, J. C.; Haworth, L.; Sherry, R. M.; Hwu, P.; Schwartzentruber, D. J.; Topalian, S. L.; Steinberg, S. M.; Chen, H. X.; Rosenberg, S. A. A randomized trial of bevacizumab (anti-VEGF antibody) in metastatic renal cancer. N. Eng. J. Med. 2003, 349, 427-434.
23. Prewett, M.; Huber, J.; Li, Y.; Santiago, A.; O'Connor, W.; King, K.; Overholser, J.; Hooper, A.; Pytowski, B.; Witte, L.; Bohlen, P.; Hicklin, D. J. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis. Cancer Res. 1999, 59, 5209-5218.
24. Holash, J.; Davis, S.; Papadopoulos, N.; Groll, S. D.; Ho, L.; Russell, M.; Boland, P.; Leidich, R.; Hylton, D.; Burova, E.; Ioffe, E.; Huang, T.; Radziejewski, C.; Baily, K.; Fandl, J. P.; Daly, T.; Wiegand, S. J.; Yancopoulos, G. D.; Rudge, J. S. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci., U.S.A. 2002, 99, 11393-11398.
25. (a) Drevs, J.; Müller-Driver, R.; Wittig, C.; Fuxius, S.; Esser, N.; Hugenschmidt, H.; Konerding, M. A.; Allegrini, P. R.; Wood, J.; Hennig, J.; Unger, C.; Marmé, D. PTK787/ZK222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, effects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res. 2002, 62, 4015-4022.
26. (b) Bold, G.; Altman, K.-H.; Frei, J.; Lang, M.; Manley, P. W.; Traxler, P.; Wietfeld, B.; Brüggen, J.; Buchdunger, E.; Cozens, R.; Ferrari, S.; Furet, P.; Hofmann, F.; Martiny-Baron, G.; Mestan, J.; Rösel, J.; Sills, M.; Stover, D.; Acemoglu, F.; Boss, E.; Emmenegger, R.; Lässer, L.; Masso, E.; Roth, R.; Schlachter, C.; Vetterli, W.; Wyss, D.; Wood, J. M. New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinase useful as antagonists of tumor-driven angiogenesis. J. Med. Chem. 2000, 43, 2310-2323.
27. (a) Mendel, D. B.; Laird, A. D.; Xin, X.; Louie, S. G.; Christensen, J. G.; Li, G.; Schreck, R. E.; Abrams, T. J.; Ngai, T. J.; Lee, L. B.; Murray, L. J.; Carver, J.; Chan, E.; Moss, K. G.; Haznedar, J. O.; Sukbuntherng, J.; Blake, R. A.; Sun, L.; Tang, C.; Miller, T.; Shirazian, S.; McMahon, G.; Cherrington, J. M. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/ pharmacodynamic relationship. Clin. Cancer Res. 2003, 9(1), 327-337.
28. (b) Sepp-Lorenzino, L.; Thomas, K. A. Expert Opin. Invest. Drugs 2002, 11, 1-18.
29. Abdollahi, A.; Lipson, K. E.; Han, X.; Krempien, R.; Trinh, T.; Weber, K. J.; Hahnfeldt, P.; Hlatky, L.; Debus, J.; Hewlett, A. R.; Huber, P. E. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer Res. 2003, 63, 3755-3763.
30. (a) Ciardiello, F.; Caputo, R.; Damiano, V.; Caputo, R.; Troiani, T.; Vitagliano, D.; Carlomagno, F.; Veneziani, B. M.; Fontanini, G.; Bianco, A. R.; Tortora, G. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin. Cancer Res. 2003, 9, 1546-1556.
31. (b) Hennequin, L. F.; Stokes, E. S.; Thomas, A. P.; Johnstone, C.; Ple, P. A.; Ogilvie, D. J.; Dukes, M.; Wedge, S. R.; Kendrew, J.; Curwen, J. O. Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J. Med. Chem. 2002, 45, 1300-1312.
32. Kabbinavar, F.; Hurwitz, H. I.; Fehrenbacher, L.; Meropol, N. J.; Novotny, W. F.; Lieberman, G.; Griffing, S.; Bergsland, E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. 2003, 21, 60-65.
33. (a) Gingrich, D. E.; Reddy, D. R.; Iqbal, M. A.; Singh, J.; Almone, L. D.; Angeles, T. S.; Albom, M.; Yang, S.; Ator, M. A.; Meyer, S. L.; Robinson, C.; Ruggeri, B. A.; Dionne, C. A.; Vaught, J. L.; Mallamo, J. P.; Hudkins, R. L. A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2, 1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055. J. Med. Chem. 2003, 46, 5375-5388.
34. (b) Boyer, S. J. Small molecule inhibitors of KDR (VEGFR-2) kinase: an overview of structure activity relationships. Curr. Top. Med. Chem. 2002, 2, 973-1000.
35. Connell, R. D. Patent focus on cancer chemotherapeutics V. Angiogenesis agents: September 2001-August 2002. Expert Opin. Ther. Pat. 2002, 12, 1763-1782.
36. Kuo, G.-H.; Wang, A.; Emanuel, S.; DeAngelis, A.; Zhang, R.; Connolly, P. J.; Murray, W. V.; Gruninger, R. H.; Sechler, J.; Fuentes-Pesquera, A.; Johnson, D.; Middleton, S. A.; Jolliffe, L.; Chen, X. Synthesis and Discovery of Pyrazine-Pyridine Biheteroaryl as a Novel Series of Potent Vascular Endothelial Growth Factor Receptor-2 Inhibitors J. Med. Chem. 2005, 48, 1886-1900.
37. Farina, V.; Krishnan, B. Large rate accelerations in the Stille reaction with tri-2-furylphosphine and triphenylarsine as palladium ligands: mechanistic and synthetic implications. J. Am. Chem. Soc. 1991, 113, 9585-9595.
38. (a) Wolfe, J. P.; Buchwald, S. L. Palladium-catalyzed amination of aryl triflates. J. Org. Chem. 1997, 62, 1264-1267.
39. (b) Aranyos, A.; Old, D. W.; Kiyomori, A.; Wolfe, J. P.; Sadighi, J. P.; Buchwald, S. L. Novel electron-rich bulky phosphine ligands facilitate the palladium-catalyzed preparation of diaryl ethers. J. Am. Chem. Soc. 1999, 121, 4369-4378.
40. Reisch, J.; Dziemba, P.; Mura, M. L.; Rao, A. R. R. Natural product chemistry. Part 159 [1]. Two methods for the synthesis of 4-azaacronycine as a potential antitumor agent. J. Heterocycl. Chem. 1993, 30, 981-983.
41. Fujita, M.; Oka, H.; Ogura, K. Palladium(0)/LiCl promoted cross-coupling reaction of (4-pyridyl)stannanes and aromatic bromides: easy access to poly(4-pyridyl)-substituted aromatics. Tetrahedron Lett. 1995, 36, 5247-5250.
42. Brown, A. D.; Dickinson, R. P.; Wythes, M. J. Indole derivatives as 5-HT-like agonists. WO 93/21178.
43. 2) bond formation: N-arylation of aromatic and unsaturated nitrogen and the reductive elimination chemistry of palladium azolyl and methyleneamido complexes. J. Am. Chem. Soc. 1998, 120, 827-828.
44. Brogi, E.; Wu, T.; Namiki, A.; Isner, J. M. Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation 1994, 90, 649-652.
45. Kilic, T.; Alberta, J. A.; Zdunek, P. R.; Acar, M.; Iannarelli, P.; O'Reilly, T.; Buchdunger, E.; Black, P. M.; Stiles, C. D. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res. 2000, 60, 5143-5150.
46. (a) Compounds 56, 57, and 58 were not evaluated further because of the strong inhibition of CYP450 enzymes were observed in human liver microsomal studies. Compounds 39 and 41 demonstrated low oral bioavailability (F < 10%) and therefore were administered through i.p. route for the in vivo studies.
47. (b) The A375 melanoma is considered to be a good target for VEGFR-2 inhibitors because it has good vascularization, which supports its rapid growth kinetics.
48. (c) Serrone, L.; Zeuli, M.; Sega, F. M.; Cognetti, F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty year experience overview. J. Exp. Clin. Cancer Res. 2000, 19, 21-34.
49. Eisch, J. J.; Gopal, H.; Russo, D. A. Preparation and aluminum chloride induced rearrangement of cyclopropylpyridines. J. Org. Chem. 1974, 39, 3110-3114.
50. Caldwell, W. S.; Bencherif, M.; Dull, G. M.; Crooks, P. A.; Lippiello, P. M.; Bhatti, B. S.; Deo, N. M.; Ravard, A. 3-Pyridyl-1-azabicycloalkane derivatives for prevention and treatment of CNS disorders. WO9900385, CAN 130:105302.
51. Chung, J. Y. L.; Zhao, D.; Hughes, D. L.; Grabowski, E. J. J. A practical synthesis of fibrinogen receptor antagonist MK-383. Selective functionalization of (S)-tyrosine. Tetrahedron 1993, 49, 5767-5776.
52. Emanuel, S.; Gruninger, R. H.; Fuentes-Pesquera, A.; Connolly, P. J.; Seamon, J. A.; Hazel, S.; Tominovich, R.; Hollister, B.; Napier, C.; Reuman, M.; Bignan, G.; Tuman, R.; Johnson, D.; Moffatt, D.; Batchelor, M.; Foley, A.; O'Connell, J.; Allen, R.; Perry, M.; Jolliffe, L.; Middleton, S. A. A VEGF-R2 kinase inhibitor potentiates the activity of the conventional chemotherapeutic agents paclitaxel and doxorubicin in tumor xenograft models. Mol. Pharm. 2004, 66, 635-647.
53. Glide; Schrodinger: Portland, OR.
54. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. Glide. A new approach for rapid, accurate docking and scoring. 1. method and assessment of docking accuracy. J. Med. Chem. 2004, 47, 1739-1749.
55. McTigue, M. A.; Wickersham, J. A.; Pinko, C.; Showalter, R. E.; Parast, C. V.; Tempczyk-Russell, A.; Gehring, M. R.; Mroczkowski, B.; Kan, C.-C.; Villafranca, J. E.; Appelt, K. Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesis. Structure 1999, 7, 319-330.
56. Still, W. C.; Tempczyk, A.; Hawley, R. C.; Hendrickson, T. Semianalytical treatment of salvation for molecular mechanics and dynamics. J. Am. Chem. Soc. 1990, 112, 6127-6129.
57. MacroModel; Schrodinger: Portland, OR.
58. Jorgensen, W. L.; Maxwell, D. S.; Tirado-Rives, J. Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J. Am. Chem. Soc. 1996, 118, 11225-11235.
59. MOE; Chemical Computing Group, Inc.: Montreal, Quebec, Canada.